US 11,789,010 B2
Methods of treatment with CD80 extracellular domain polypeptides
Thomas Brennan, Cupertino, CA (US); Barbara Sennino, San Francisco, CA (US); Susannah D. Barbee, San Francisco, CA (US); and Ursula Jeffry, San Francisco, CA (US)
Assigned to Five Prime Therapeutics, Inc., South San Francisco, CA (US)
Appl. No. 16/608,911
Filed by Five Prime Therapeutics, Inc., South San Francisco, CA (US)
PCT Filed Apr. 27, 2018, PCT No. PCT/US2018/029897
§ 371(c)(1), (2) Date Oct. 28, 2019,
PCT Pub. No. WO2018/201014, PCT Pub. Date Nov. 1, 2018.
Claims priority of provisional application 62/491,479, filed on Apr. 28, 2017.
Prior Publication US 2020/0182858 A1, Jun. 11, 2020
Int. Cl. G01N 33/50 (2006.01); G01N 15/10 (2006.01); G01N 15/00 (2006.01)
CPC G01N 33/5011 (2013.01) [G01N 15/10 (2013.01); G01N 2015/0065 (2013.01); G01N 2015/1006 (2013.01); G01N 2333/70532 (2013.01); G01N 2800/52 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method of increasing central memory T cell (Tcm) frequency and/or proliferation in a subject, which method comprises administering a CD80 extracellular domain (ECD) fusion molecule to the subject in an amount effective to increase Tcm frequency and/or proliferation, wherein the CD80 ECD fusion molecule comprises a human CD80 ECD polypeptide and a human IgG1 Fc domain.